Back Bay on Bloomberg Baystate Business: Rare Disease Treatments

Back Bay CEO Jonathan P. Gertler, MD and Back Bay Senior Vice President, Stephan Gauldie, PhD spoke with Bloomberg biotech reporter, Anne Mostue, about the pace of innovation for rare disease treatments. You can hear and share the interview on Bloomberg Baystate Business.

Related links:

A Rare-Disease Approach to Seizure Treatment

The FDA Releases Revised Draft Guidance for Rare Diseases